DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Electroconvulsive Therapy in Clozapine-resistant Schizophrenia

Information source: Niuvanniemi Hospital
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia; Schizoaffective Disorder

Intervention: electroconvulsive therapy (Device)

Phase: N/A

Status: Recruiting

Sponsored by: Niuvanniemi Hospital

Overall contact:
Eila Tiihonen, MD, PhD, Phone: +358 295 242 204, Email: eila.tiihonen@niuva.fi

Summary

Electroconvulsive therapy (ECT) is one of the oldest neuromodulation treatments still used in psychiatry. Only case reports and open label non-randomized studies have been published of ECT in clozapine-resistant schizophrenia patients. The purpose of this trial is to study the efficacy and cognitive effects of add-on ECT treatment (10-course) in schizophrenia patients taking clozapine.

Clinical Details

Official title: Efficacy and Cognitive Effects of Electroconvulsive Therapy in Clozapine-Resistant Schizophrenia

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: Positive and Negative Symptom Scale

Eligibility

Minimum age: 18 Years. Maximum age: 64 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- diagnosis of schizophrenia or schizoaffective disorder

- treatment-resistant to clozapine

- age 18 - 64 years

- capacity and willingness to give informed consent

Exclusion Criteria:

- serious somatic illness

- progressive neurological illness, recent brain damage or sequela of serious brain

damage

- ECT less than 3 months prior to this trial

Locations and Contacts

Eila Tiihonen, MD, PhD, Phone: +358 295 242 204, Email: eila.tiihonen@niuva.fi

Niuvanniemi Hospital, Kuopio, Finland; Recruiting
Soile Hyvärinen, MD, Phone: +358 295 242 219, Email: soile.hyvarinen@niuva.fi
Soile Hyvärinen, MD, Sub-Investigator
Eila Tiihonen, MD, PhD, Principal Investigator
Additional Information

Starting date: June 2014
Last updated: June 5, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017